THYROFIX 175 micrograms, tablet 100 tablets
Active ingredients: Levothyroxine sodium, Levothyroxine sodium
Commercialized according to BDPMDispensing in France: Prescription only
Tablet100 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- THYROFIX 175 microgrammes, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC TE (thermo-élastique) PVDC aluminium de 100 comprimé(s)
- Marketing authorisation holder
- UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES (GRECE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 8 Jun 2020
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64823053CIP73020062CIP133400930200629Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVOTHYROXINE SODIQUEcomprimé | — | SA |
| LÉVOTHYROXINE SODIQUE ANHYDREcomprimé | 175 microgrammes · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.